Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).
Solvonis Therapeutics plc announced positive pre-clinical results from its SVN-SDN-14 PTSD programme, identifying three high-performing candidates for in vivo studies. These candidates, which modulate serotonin, dopamine, and noradrenaline pathways, aim to enhance pro-social behavior and improve therapeutic outcomes for PTSD patients. The advancement of multiple candidates strengthens the company’s position and increases the likelihood of selecting a commercially viable treatment option.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Based in London and listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet needs, including Alcohol Use Disorder and Post-Traumatic Stress Disorder. The company employs a capital-efficient model and a dual development strategy, leveraging an AI-supported discovery platform to expand its R&D pipeline.
Average Trading Volume: 93,560,905
Technical Sentiment Signal: Hold
Current Market Cap: £20.66M
For detailed information about SVNS stock, go to TipRanks’ Stock Analysis page.